Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes | Zendy

Egilius L.H. Spierings | Zendy; Douglas A. Drossman | Zendy; Byron Cryer | Zendy; M. Mazen Jamal | Zendy; Taryn LoschBeridon | Zendy; Shadreck M. Mareya | Zendy; Martin Wang | Zendy

Open Access

Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes

Author(s) -

Egilius L.H. Spierings,

Douglas A. Drossman,

Byron Cryer,

M. Mazen Jamal,

Taryn LoschBeridon,

Shadreck M. Mareya,

Martin Wang

Publication year - 2017

Publication title -

pain medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.893

H-Index - 97

eISSN - 1526-4637

pISSN - 1526-2375

DOI - 10.1093/pm/pnx156

Subject(s) - lubiprostone , medicine , placebo , methadone , clinical endpoint , opioid , constipation , anesthesia , clinical trial , gastroenterology , chronic constipation , alternative medicine , receptor , pathology

The efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study. These data were also pooled with those from two similar phase 3 studies to explore the effects of methadone on treatment response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research